EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model

Seth-Frerich Fobian, Mohamadreza Amin, Andrea Sacchetti, Arlene L Oei, Timo L M Ten Hagen

Journal of Controlled Release · 2025-03 · 379 · 236-250

DOI: 10.1016/j.jconrel.2025.01.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Seth-Frerich Fobian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Eras…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness of immunotherapies for more durable and less radical interventions. In this study, the targeting potential of anti-PD-L1-functionalized immunoliposomes was tested in a 3D in vitro cervical cancer-on-a-chip model. Immunolipsomes were synthesized and decorated externally with monovalent anti-PD-L1 Fab' fragments of commercially available atezolizumab. Cervical cancer cell lines with varying levels of PD-L1 expression were cultured as spheroids embedded in a collagen I matrix, and treated under flow of culture media. Flow cytometry and live-cell confocal imaging were used to measure the interactions and uptake of untargeted liposomes and immunoliposomes in this panel of cell lines. The immunoliposomes retained specific functionality regardless of protein corona formation in high serum environments. As such, spheroids expressing high levels of PD-L1 preferentially internalized immunoliposomes in a 3D environment with extracellular matrix present, while low PD-L1-expressing cell lines showed no preference for either formulation. Importantly, treatments performed in monolayer cultures (on plastic) showed no differences between immuno- and untargeted liposome uptake, including the way in which the endocytosed liposomes are trafficked subcellularly. This study demonstrates the importance of both active and passive accumulation strategies to achieve nanoparticle targeting. Immunoliposomes remain a promising platform for the development of targeted nanotherapies against cervical cancers. However, initial functional tests did not translate directly to biological performance and this should be kept in mind for future formulations. Furthermore, the in vitro model developed appeared useful for visualizing liposome uptake in a 3D, live tissue environment and represents a cost-effective and reproducible model for future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenUterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedHumansLiposomesFemaleCell Line, TumorLab-On-A-Chip DevicesSpheroids, CellularDrug Delivery Systems

Stichwörter der Autor:innen

Cervical cancerDrug deliveryImmunotherapyLiposomesNanomedicine

Substanzen

LiposomesB7-H1 AntigenCD274 protein, humanAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands; Dep…
  • Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
  • Department of Pathology, Erasmus MC, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands.
  • Department of Radiation Oncology, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Center for Experimental and Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR),…
  • Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Ele…

Förderung

  • National Research Foundation

Zitieren

APA

Fobian, S. F., Amin, M., Sacchetti, A., Oei, A. L., & Ten Hagen, T. L. M. (2025). Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model. Journal of Controlled Release, 379, 236-250. https://doi.org/10.1016/j.jconrel.2025.01.014

Vancouver

Fobian SF, Amin M, Sacchetti A, Oei AL, Ten Hagen TLM. Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model. Journal of Controlled Release. 2025;379:236-250. doi:10.1016/j.jconrel.2025.01.014

BibTeX
@article{Fobian2025,
  author = {Fobian, Seth-Frerich and Amin, Mohamadreza and Sacchetti, Andrea and Oei, Arlene L and Ten Hagen, Timo L M},
  title = {Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {379},
  pages = {236--250},
  doi = {10.1016/j.jconrel.2025.01.014}
}
Kostenlos starten →